LITH — Bioelife Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$0.02m
Annual income statement for Bioelife, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2014 December 31st | 2015 December 31st | 2016 December 31st | 2017 December 31st | 2018 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.464 | 0.043 | 0.104 | 0.125 | -0.602 |
| Operating Profit | -0.464 | -0.043 | -0.104 | -0.125 | 0.602 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.498 | -0.082 | -0.21 | -0.247 | -0.337 |
| Net Income After Taxes | -0.498 | -0.082 | -0.21 | -0.247 | -0.337 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.498 | -0.082 | -0.21 | -0.247 | -0.337 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.498 | -0.082 | -0.21 | -0.247 | -0.337 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.442 | -0.053 | -0.092 | -0.101 | -0.389 |
| Dividends per Share |